Ovarian cryopreservation is one of the available option for preserving fertility prior to potentially sterilizing treatments. In the absence of other techniques such as in vitro folliculogenesis or injection of isolated ovarian follicles, this tissue can only be re-used by autograft. In France, the first live birth after orthotopic ovarian transplantation, was obtained by Roux et al. in 2009. This clinical trial aims to build a cohort of patients likely to use their ovarian tissue cryopreserved by autograft.
Ovarian cryopreservation is one of the available option for preserving fertility prior to potentially sterilizing treatments. In the absence of other techniques such as in vitro folliculogenesis or injection of isolated ovarian follicles, this tissue can only be re-used by autograft. In France, the first live birth after orthotopic ovarian transplantation, was obtained by Roux et al. in 2009. This clinical trial aims to build a cohort of patients likely to use their ovarian tissue cryopreserved by autograft. This cohort will be used to: * Follow up of patients with their cryopreserved ovarian tissue; * Evaluate requests for ovarian tissue grafting ; * Propose a search of residual disease in case of neoplastic disease risk (if possible); * Allowing patients to benefit from an ovarian tissue autograft; * Assess the effectiveness of autograft technique after the restoration of ovarian function.
Study Type
OBSERVATIONAL
Enrollment
240
CHRU Besancon
Besançon, France
RECRUITINGNumber of patient who are candidate to ovarian tissue autograft
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.